口服普萘洛尔治疗斯特奇-韦伯综合征中弥漫性脉络膜血管瘤所致渗出性视网膜脱离
Oral propranolol therapy for management of exudative retinal detachment from diffuse choroidal hemangioma in Sturge-Weber syndrome.
作者信息
Thapa Raba, Shields Carol L
机构信息
Tilganga Institute of Ophthalmology, Kathmandu - Nepal.
出版信息
Eur J Ophthalmol. 2013 Nov-Dec;23(6):922-4. doi: 10.5301/ejo.5000322. Epub 2013 Jun 2.
PURPOSE
Diffuse choroidal hemangioma (DCH), a feature of Sturge-Weber syndrome, is most often treated with whole-eye radiotherapy at stage of complications such as retinal detachment.
METHODS
This is a case report of a 17-year-old boy with DCH and exudative retinal detachment.
RESULTS
The patient was treated with propranolol at 60 mg twice a day for 2 months followed by gradual dose taper to 10 mg twice a day per month and discontinued at 7 months. The retinal detachment slowly resolved over 1 month and the retina remained attached at 10 months follow-up. There were no medication side effects.
CONCLUSIONS
We suggest that oral propranolol be considered in the armamentarium for selected DCH.
目的
弥漫性脉络膜血管瘤（DCH）是斯-韦综合征的一个特征，在出现视网膜脱离等并发症阶段，最常采用全眼放疗进行治疗。
方法
本文是一例患有弥漫性脉络膜血管瘤和渗出性视网膜脱离的17岁男孩的病例报告。
结果
该患者接受普萘洛尔治疗，初始剂量为60毫克，每日两次，持续2个月，随后每月逐渐减量至每日两次，每次10毫克，并在7个月时停药。视网膜脱离在1个月内缓慢消退，在10个月的随访中视网膜保持附着状态。未出现药物副作用。
结论
我们建议，对于特定的弥漫性脉络膜血管瘤患者，可考虑将口服普萘洛尔纳入治疗手段。
Zotero 插件